Risk factors of death in HIV/HCV co-infected patients with combined antiretroviral therapy
10.3760/cma.j.issn.1674-2397.2012.03.007
- VernacularTitle:HIV/HCV合并感染者联合抗反转录病毒治疗后死亡原因及危险因素分析
- Author:
Liping DENG
;
Xien GUI
;
Yong XIONG
;
Shicheng GAO
;
Yuping RONG
;
Rongrong YANG
;
Jinzhi HU
- Publication Type:Journal Article
- Keywords:
HIV;
Hepatitis C virus;
Combined antiretroviral therapy;
Death;
Risk factors
- From:
Chinese Journal of Clinical Infectious Diseases
2012;05(3):153-157
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the incidence,mortality and risk factors of death in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) co-infected patients with combined antiretroviral therapy (cART).Methods A total of 427 HIV/HCV co-infected patients admitted to Zhongnan Hospital of Wuhan University or local disease prevention and control canters from January 2003 to December 2010 were enrolled in the study.The demographic and clinical data of patients were retrospectively studied.Cox progressive regression model was used for data analysis,and Kaplan-Meier method was used to evaluate the effect of end-stage liver diseases on the death.Results of 427 HIV/HCV co-infected patients,53 ( 12.4％ ) died during the follow-up,in which 28 (52.8％) died of liver-related diseases.Male gender ( RR =2.63,P =0.05 ),infection via blood transfusion ( RR =2.15,P =0.04),baseline CD4 + T cells ＜50 cells/μL ( RR =2.83,P =0.02),HIV RNA≥ 104copies/mL at the end of follow-up (RR =2.79,P =0.00 ) and complicated with end-stage liver disease ( RR =7.79,P =0.00) were significantly related to the death.Duration of cART ＞ 5 years is a protective factor for the death ( RR =0.03,P =0.00).Themortality of patients complicated with end-stage liver diseases was 52.7％ ( 29/55 ).Conclusion Liver disease-related death has become the leading cause of death in HIV/HCV co-infected patients,and patients with end-stage liver diseases are of high risk of death.
